FDA approves first drug for Type 3 Gaucher neurological symptoms

Infilbray (venglustat), from Genzyme, is approved for adults and pediatric patients weighing at least 15 kilograms. Approval rests on a 52-week trial of 43 patients aged 12 and older.

By Theo Adeyemi, Regulation and biotech correspondent
. 2-minute read.
Entrance to the Genzyme building at 500 Kendall Square, Cambridge, Massachusetts
The entrance to Genzyme's building at 500 Kendall Square in Cambridge, Massachusetts. Photograph: Tim Pierce/Wikimedia Commons (public domain)

On November 18, 2026, the FDA approved Infilbray (venglustat) tablets as the first therapy aimed at the neurological manifestations of Type 3 Gaucher disease (GD3), with a weight threshold of 15 kilograms for patients, according to the agency's news release. The approval was granted to Genzyme Corporation, a Sanofi Company.

Infilbray inhibits glucosylceramide synthase and can penetrate the blood-brain barrier, thereby decreasing deposits of fatty compounds known as glucosphingolipids in both the body and the brain. Individuals with GD3 lack a functioning enzyme, so their bodies fail to metabolize these lipids normally. In contrast to type 1 Gaucher disease, GD3 involves the central nervous system, leading to progressive problems with balance, coordination, speech, memory, and cognition.

The agency based its decision on a randomized, double-blind, multicenter trial (NCT05222906) that enrolled 43 patients age 12 or older with GD3. All had received enzyme replacement therapy before and had stable systemic disease. For 52 weeks, participants took either Infilbray by mouth each day or enzyme replacement therapy intravenously every other week. Researchers measured efficacy with two scales that reflect everyday neurological symptoms, including ataxia and cognitive impairment. At week 52, the Infilbray group showed greater improvement on a combined score than patients who continued enzyme replacement therapy for non-neurologic symptoms. The FDA release did not report the size of the improvement or separate results for ataxia and cognition.

Common side effects were gastrointestinal issues and mood changes. Serious psychiatric events, such as suicidal thoughts and actions, have occurred. Animal studies suggest possible vision clouding in younger patients and harm to fetal development if used during pregnancy.

Infilbray received Orphan Drug designation and Priority Review. Acting FDA Commissioner Kyle Diamantas said: "For patients with Type 3 Gaucher disease, harmful substances build up in the brain without a way to stop them, but this drug's ability to cross the blood-brain barrier means it can get to the source of the buildup driving the neurological symptoms." He added that the approval "brings an important new treatment to patients and the healthcare providers who care for them".

The approval followed an FDA decision the previous day for Lembaz (adrabetadex) injection in infantile-onset Niemann-Pick disease type C, as covered by Clinical Observer. Lembaz is administered by a healthcare professional as an intrathecal injection every two weeks and includes a boxed warning about hearing loss.

Sources: FDA, Clinical Observer

Theo AdeyemiRegulation and biotech correspondent

Theo Adeyemi covers drug regulation and the biotech industry for Clinical Observer. He writes from regulators' notices, company filings and published reporting.

Corrections. Report an error to corrections@clinicalobserver.com. Read our corrections policy.